# A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06111274/  
OnCo record `nct06111274` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pimicotinib (ABSK021) in pancreatic ductal adenocarcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.

## Summary

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT06111274 by Abbisko Therapeutics Co, Ltd, with 82 participants planned, started 2023-10-17 and due to reach its primary completion in 2025-12-30. Interventions recorded: Pimicotinib (ABSK021).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06111274
- Phase: 2
- Setting: A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 82

## Sources

- ClinicalTrials.gov NCT06111274: https://clinicaltrials.gov/study/NCT06111274

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)

---
JSON: https://onco.cc/api/v1/entities/nct06111274.json